251 related articles for article (PubMed ID: 20954411)
1. [Significance of serum tumor markers monitoring metastases in carcinomas of unknown primary site].
Pejcić I; Vrbić S; Filipović S; Sćekić M; Petković I; Pejcić L; Djenić N
Vojnosanit Pregl; 2010 Sep; 67(9):723-31. PubMed ID: 20954411
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of six tumor markers in patients with carcinoma of unknown primary.
Pavlidis N; Kalef-Ezra J; Briassoulis E; Skarlos D; Kosmidis P; Saferiadis K; Bairaktari E; Bafaloukos D; Maravegias A; Theoharis D
Med Pediatr Oncol; 1994; 22(3):162-7. PubMed ID: 7505876
[TBL] [Abstract][Full Text] [Related]
3. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma.
Fizazi K; Cojean I; Pignon JP; Rixe O; Gatineau M; Hadef S; Arriagada R; Baldeyrou P; Comoy E; Le Chevalier T
Cancer; 1998 Mar; 82(6):1049-55. PubMed ID: 9506348
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy in carcinomas of unknown primary site.
Pejcić I; Vrbić S; Filipović S; Radić S; Pejcić Lj
J BUON; 2004; 9(1):27-31. PubMed ID: 17385824
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of serum tumor markers in patients with lung cancer.
Hatzakis KD; Froudarakis ME; Bouros D; Tzanakis N; Karkavitsas N; Siafakas NM
Respiration; 2002; 69(1):25-9. PubMed ID: 11844959
[TBL] [Abstract][Full Text] [Related]
6. Metastatic adeno or undifferentiated carcinoma from an unknown primary site--natural history and guidelines for identification of treatable subsets.
Kirsten F; Chi CH; Leary JA; Ng AB; Hedley DW; Tattersall MH
Q J Med; 1987 Feb; 62(238):143-61. PubMed ID: 3659256
[TBL] [Abstract][Full Text] [Related]
7. [Combination chemotherapy with ifosfamide, 5-fuluorouracil, etoposide and cisplatin for advanced urothelial cancer: the treatment results and significance of tumor marker evaluation in response assessment of chemotherapy].
Maezawa T; Yonese J; Tsukamoto T; Ishii N; Fukui I
Nihon Hinyokika Gakkai Zasshi; 2002 Nov; 93(7):727-35. PubMed ID: 12494517
[TBL] [Abstract][Full Text] [Related]
8. [Serial measurements of serum carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) during chemotherapy of patients with inoperable lung cancer].
Fukuoka M; Takada M; Kamei T; Negoro S; Kusunoki Y; Matsui K; Ryu S; Sakai N; Takifuji N; Masuda N
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):871-80. PubMed ID: 3032108
[TBL] [Abstract][Full Text] [Related]
9. Tumor markers in metastatic disease from cancer of unknown primary origin.
Milović M; Popov I; Jelić S
Med Sci Monit; 2002 Feb; 8(2):MT25-30. PubMed ID: 11859288
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of prognostic factors in 68 patients with cancer of unknown primary site].
Kou XG; Liang DL; Zhang QQ; Li XR; Zhao YZ; Gu JF; Lu P
Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):783-6. PubMed ID: 22335913
[TBL] [Abstract][Full Text] [Related]
11. [Undifferentiated carcinoma of cervical node metastases in patients with an unknown primary lesion: an immunohistochemical study].
Nakamizo M; Kamata SE; Kawabata K; Takahashi H; Nigauri T; Hoki K; Yanagisawa A
Nihon Jibiinkoka Gakkai Kaiho; 1994 Dec; 97(12):2202-7. PubMed ID: 7861291
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience.
Hainsworth JD; Johnson DH; Greco FA
J Clin Oncol; 1992 Jun; 10(6):912-22. PubMed ID: 1375284
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis of a previously unidentified primary site in patients with spinal metastasis: diagnostic usefulness of laboratory analysis, CT scanning and CT-guided biopsy.
Iizuka Y; Iizuka H; Tsutsumi S; Nakagawa Y; Nakajima T; Sorimachi Y; Ara T; Nishinome M; Seki T; Takagishi K
Eur Spine J; 2009 Oct; 18(10):1431-5. PubMed ID: 19533181
[TBL] [Abstract][Full Text] [Related]
14. Clinical usefulness of serum assays of neuron-specific enolase, carcinoembryonic antigen and CA-50 antigen in the diagnosis of lung cancer.
Bergman B; Brezicka FT; Engström CP; Larsson S
Eur J Cancer; 1993; 29A(2):198-202. PubMed ID: 8380696
[TBL] [Abstract][Full Text] [Related]
15. [Carcinoma of unknown primary site. Apropos of 100 patients treated at the Montpellier regional center of cancer prevention].
Culine S; Gazagne L; Ychou M; Romieu G; Fabbro M; Cupissol D; Dubois JB
Rev Med Interne; 1998 Oct; 19(10):713-9. PubMed ID: 9827443
[TBL] [Abstract][Full Text] [Related]
16. Acquired renal cystic disease and tumor markers in chronic hemodialysis patients.
Polenakovic M; Sikole A; Dzikova S; Polenakovic B; Gelev S
Int J Artif Organs; 1997 Feb; 20(2):96-100. PubMed ID: 9093887
[TBL] [Abstract][Full Text] [Related]
17. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder.
Pectasides D; Bafaloucos D; Antoniou F; Gogou L; Economides N; Varthalitis J; Dimitriades M; Kosmidis P; Athanassiou A
Am J Clin Oncol; 1996 Jun; 19(3):271-7. PubMed ID: 8638540
[TBL] [Abstract][Full Text] [Related]
18. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy.
Murphy BA; Motzer RJ; Mazumdar M; Vlamis V; Nisselbaum J; Bajorin D; Bosl GJ
Cancer; 1994 May; 73(10):2520-6. PubMed ID: 7513603
[TBL] [Abstract][Full Text] [Related]
19. Tumor markers in response monitoring and prognosis of non-small cell lung cancer: preliminary report.
Viñolas N; Molina R; Galán MC; Casas F; Callejas MA; Filella X; Grau JJ; Ballesta AM; Estape J
Anticancer Res; 1998; 18(1B):631-4. PubMed ID: 9584045
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer.
Lilleby W; Paus E; Skovlund E; Fosså SD
Prostate; 2001 Feb; 46(2):126-33. PubMed ID: 11170140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
